全文获取类型
收费全文 | 95750篇 |
免费 | 7846篇 |
国内免费 | 5078篇 |
专业分类
耳鼻咽喉 | 699篇 |
儿科学 | 2003篇 |
妇产科学 | 1237篇 |
基础医学 | 8512篇 |
口腔科学 | 1178篇 |
临床医学 | 9963篇 |
内科学 | 16072篇 |
皮肤病学 | 899篇 |
神经病学 | 2340篇 |
特种医学 | 5891篇 |
外国民族医学 | 52篇 |
外科学 | 15121篇 |
综合类 | 14770篇 |
现状与发展 | 19篇 |
预防医学 | 3097篇 |
眼科学 | 602篇 |
药学 | 7003篇 |
56篇 | |
中国医学 | 3045篇 |
肿瘤学 | 16115篇 |
出版年
2024年 | 183篇 |
2023年 | 1328篇 |
2022年 | 2932篇 |
2021年 | 3925篇 |
2020年 | 3220篇 |
2019年 | 2852篇 |
2018年 | 2752篇 |
2017年 | 2879篇 |
2016年 | 3390篇 |
2015年 | 3706篇 |
2014年 | 6127篇 |
2013年 | 5847篇 |
2012年 | 5625篇 |
2011年 | 6072篇 |
2010年 | 5181篇 |
2009年 | 5234篇 |
2008年 | 5291篇 |
2007年 | 5500篇 |
2006年 | 5045篇 |
2005年 | 4345篇 |
2004年 | 3485篇 |
2003年 | 2984篇 |
2002年 | 2757篇 |
2001年 | 2465篇 |
2000年 | 2047篇 |
1999年 | 1783篇 |
1998年 | 1551篇 |
1997年 | 1430篇 |
1996年 | 1226篇 |
1995年 | 1127篇 |
1994年 | 993篇 |
1993年 | 760篇 |
1992年 | 639篇 |
1991年 | 516篇 |
1990年 | 413篇 |
1989年 | 395篇 |
1988年 | 381篇 |
1987年 | 297篇 |
1986年 | 236篇 |
1985年 | 290篇 |
1984年 | 247篇 |
1983年 | 149篇 |
1982年 | 204篇 |
1981年 | 186篇 |
1980年 | 128篇 |
1979年 | 121篇 |
1978年 | 110篇 |
1977年 | 79篇 |
1976年 | 71篇 |
1974年 | 36篇 |
排序方式: 共有10000条查询结果,搜索用时 187 毫秒
51.
《中国现代医生》2020,58(34):112-115
目的 探讨地佐辛术后镇痛对高龄患者围术期肝功能的影响。方法 选择2018 年1 月~2020 年6 月吉安市中心人民医院麻醉科收治的ASA 分级Ⅱ~Ⅲ级高龄患者80 例,按照随机数字表法,分为A 组、B 组、C 组、D 组,每组各20 例。分别给予0.4 mg/kg、0.5 mg/kg、0.6 mg/kg、0.7 mg/kg 地佐辛进行术后镇痛,评估术后1、2、6、12、24、48 h 患者的疼痛程度[视觉模拟评分法(VAS)]、术后镇静效果(Ramsay 评分法)及肝功能指标(ALT、AST)水平,评价不同剂量的地佐辛术后镇痛对高龄患者围术期肝功能的影响。结果 C 组术后患者不同时间段VAS 疼痛评分低于A 组、B 组、D 组,差异有统计学意义(P<0.05);四组患者术后1、2、6 h Ramsay 镇静评分比较,差异有统计学意义(P<0.05);但术后12、24、48 h Ramay 镇痛评分比较,差异无统计学意义(P>0.05)。C 组肝功能指标ALT、AST优于A 组、B 组、D 组,差异有统计学意义(P<0.05)。结论 高龄患者术后镇痛应用0.6 mg/kg地佐辛对围术期肝功能的影响最小。 相似文献
52.
53.
《药学学报(英文版)》2020,10(7):1294-1308
A great challenge in multi-targeting drug discovery is to identify drug-like lead compounds with therapeutic advantages over single target inhibitors and drug combinations. Inspired by our previous efforts in designing antitumor evodiamine derivatives, herein selective histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) dual inhibitors were successfully identified, which showed potent in vitro and in vivo antitumor potency. Particularly, compound 30a was orally active and possessed excellent in vivo antitumor activity in the HCT116 xenograft model (TGI = 75.2%, 150 mg/kg, p.o.) without significant toxicity, which was more potent than HDAC inhibitor vorinostat, TOP inhibitor evodiamine and their combination. Taken together, this study highlights the therapeutic advantages of evodiamine-based HDAC1/TOP2 dual inhibitors and provides valuable leads for the development of novel multi-targeting antitumor agents. 相似文献
54.
Taisuke Inada Satoshi Fukushima Masayuki Murai Masatoshi Jinnin Azusa Miyashita Satoshi Nakahara Junji Yamashita Jun Aoi Shinichi Masuguchi Hironobu Ihn 《The Journal of dermatology》2015,42(2):198-201
miRNA‐221 (miR‐221) is known to be abnormally expressed in many human cancers. The serum levels of miR‐221 have been reported as a tumor marker for malignant melanoma (MM). We hypothesized that the hair shaft miR‐221 levels may be increased in patients with MM. We therefore assessed the possibility that hair shaft miR‐221 levels could be a marker for MM. The hair shaft miR‐221 levels were significantly higher in patients with MM than controls. The rates of increased hair shaft miR‐221 levels above the cut‐off value were comparable to those of serum 5‐S‐CD, which is a tumor marker commonly used for MM. Measurements of the hair shaft miR‐221 levels could have potential clinical value in the detection of MM. This is the first report investigating the hair shaft levels of an miRNA in patients with MM. Our investigations offer new insight into the relationship between miR‐221 and MM, and may provide a new, non‐invasive way to screen for melanoma. 相似文献
55.
56.
You-Wen Tan 《World Journal of Meta-Analysis》2021,9(6):488-495
Nilotinib is a specific breakpoint cluster region-Abelson leukemia virus-tyrosine kinase inhibitor that is used as an effective first- or second-line treatment in imatinib-resistant chronic myelogenous leukemia (CML) patients. Hepatotoxicity due to nilotinib is a commonly reported side effect; however, abnormal liver function test (LFT) results have been reported in asymptomatic cases. When alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels are more than five-fold the upper limit of the normal (ULN) or when the serum total bilirubin level is more than three-fold the ULN, dose modification or discontinuation of nilotinib is recommended, resulting in decreased levels of hematological indicators in certain patients with CML. Nilotinib-induced hyperbilirubinemia typically manifests as indirect bilirubinemia without elevated ALT or AST levels. Such abnormal liver functioning is thus not attributed to the presence of a true histologic lesion of the liver. The underlying mechanism may be related to the inhibition of uridine diphosphate glucuronosyltransferase activity. Therefore, nilotinib dose adjustment is not recommended for this type of hyperbilirubinemia, and in the absence of elevated liver enzyme levels or presence of abnormal LFT findings, physicians should consider maintaining nilotinib dose intensity without modifications. 相似文献
57.
58.
Roberto V.P. Ribeiro Mitesh V. Badiwala Danny Ramzy Laura C. Tumiati Vivek Rao 《The Journal of thoracic and cardiovascular surgery》2019,157(2):615-625.e1
Objective
Hypertonic saline (HTS) has potent immune and vascular effects. We assessed recipient pretreatment with HTS on allograft function in a porcine model of heart transplantation and hypothesized that HTS infusion would limit endothelial and left ventricular (LV) dysfunction following transplantation.Methods
Heart transplants were performed after 6 hours of cold ischemic storage. Recipient pigs were randomized to treatment with or without HTS (7.5% NaCl) before cardiopulmonary bypass (CPB). Using a myograft apparatus, coronary artery endothelial-dependent (Edep) and -independent (Eind) relaxation was assessed. LV performance was determined using pressure-volume loop analysis. Pulmonary interleukin (IL)-2, IL-6, and tumor necrosis factor (TNF)-α expression was measured.Results
Weaning from CPB and LV performance after transplantation were improved in HTS-treated animals. Successful weaning from CPB was greater in the HTS-treated hearts (8 of 8 vs 2 of 8; P < .05). Mean LV functional recovery was improved in the HTS-treated animals, as assessed by preload recruitable stroke work (65 ± 10% vs 27 ± 10%; P < .001) and end-systolic elastance (55 ± 7% vs 37 ± 4%; P < .001). Treatment with HTS resulted in improved Edep (mean maximum elastance [Emax], 56 ± 5% vs 37 ± 7%; P < .001) and Eind (mean Emax%, 77 ± 6% vs 52 ± 4%; P < .001) vasorelaxation compared with control. Pulmonary expression of IL-2, IL-6, and TNF-α increased following transplantation, whereas HTS therapy attenuated IL production (P < .001). Transplantation increased plasma TNF-α levels and LV TNF-α expression, whereas HTS prevented this up-regulation (P < .001).Conclusions
Recipient HTS pretreatment preserves allograft vasomotor and LV function, and HTS therapy limits CPB-induced injury. HTS may be a novel recipient intervention to prevent graft dysfunction. 相似文献59.
60.
�� ��a������ٻb��������a��������a������������ �� 《中国实用外科杂志》2019,39(2):194-196